secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001104659-26-049756
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet Biosciences prices public offering of 29.2M shares at $6.00/share for ~$164.5M net proceeds
--------------------------------------------------------------------------------

- Offering of 29,166,700 shares of common stock at $6.00 per share; net proceeds expected $164.5 million.
- Net proceeds to fund Phase 3 trial of denifanstat in acne, TVB-3567 through Phase 2, and topical FASN inhibitor to IND.
- Joint book-running managers: Leerink Partners, TD Securities, Guggenheim Securities, and Oppenheimer & Co.
- Co-lead managers: Canaccord Genuity, H.C. Wainwright, and JonesTrading.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465926049756/0001104659-26-049756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465926049756/tm2612794d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-049756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer